PVI
YMAB

Pura Vida Investments’s Y-mAbs Therapeutics YMAB Stock Holding History

Pura Vida Investments’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-22,350
Closed -$594K – 112
2018
Q3 		$594K Buy
+22,350
New +$568K 0.13% 97

Other funds holding YMAB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pura Vida Investments's YMAB Position: Q4 2018 in Review

Pura Vida Investments sold out of Y-mAbs Therapeutics (YMAB) in Q4 2018, closing a stake of 22,350 shares — an estimated $594K sold.

Pura Vida Investments first reported a position in YMAB in Q3 2018 and held it in 1 quarter. The position peaked at $594K in Q3 2018. 42 funds tracked by Wall St. Rank hold YMAB as of Q4 2018.

  • Pura Vida Investments reported no remaining Y-mAbs Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Pura Vida Investments sold 22,350 Y-mAbs Therapeutics shares in Q4 2018, an estimated $594K.
  • Pura Vida Investments first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 1 quarter.
  • Pura Vida Investments's Y-mAbs Therapeutics position peaked at $594K in Q3 2018.
  • 42 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2018.

Based on Pura Vida Investments's 13F filing for Q4 2018, filed 14 Feb 2019.